314 / 1266
Pituitary
03/01/13
Study
41’000 patients/9 studies (pituitary-
hypothalamic tumors)
NFPA
10y TPFS 70% vs. 74% (NS)
Craniopharyngioma
TP not affected by GHR
(Significant factor: residual tumor, RT)
NFPA
GH not predictor of tumor progression
after ajusting for gender, resction, age,
invasion cav. Sinus)
Secondary tumors in patients with RT +/-
GHR (match pait analysis)
No difference observed